NCT00293813View on ClinicalTrials.gov

A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

PHASE2CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

August 31, 2008

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Alendronate

Alendronate 70 mg PO QW

DRUG

Denosumab

denosumab 60 mg SC q 6 mos

DRUG

Placebo

Placebo for alendronate and placebo for denosumab

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00293813 - A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density | Biotech Hunter | Biotech Hunter